Wed, January 8, 2020

Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Increased Target to $30 on, Jan 8th, 2020

Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Increased Target from $25 to $30 on, Jan 8th, 2020.

Raghuram has made no other calls on BTAI in the last 4 months.



There is 1 other peer that has a rating on BTAI. Out of the 1 peers that are also analyzing BTAI, 0 agree with Raghuram's Rating of Hold.



This is the rating of the analyst that currently disagrees with Raghuram


  • Robyn Karnauskas of "SunTrust Robinson Humphrey" Initiated at Strong Buy and Held Target at $24 on, Tuesday, November 12th, 2019